Covid-19

#Covid-19 #Disease X #Pandemic prevention #Pandemic response

New podcast on Disease X: The 100 Days Mission to End Pandemics

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this latest episode, DDW’s Megan Thomas is in conversation with Kate Kelland, author of Disease… Read More

#News

#Astex Pharmaceuticals #Covid-19 #Drug discovery #Life sciences #Public health

Sitting down with… Dr Harren Jhoti, Astex Pharmaceuticals

Listen to this article on the DDW Podcast: Following his recent OBE, Diana Spencer speaks to Dr Harren Jhoti about his career, the UK life sciences sector, fragment-based drug discovery and what the future holds for the industry. At the end of 2022, Astex Pharmaceuticals co-founder, President and CEO Dr Harren… Read More

#Cancer Research #Exclusive Content

Covid-19
#Axcella Therapeutics #Covid-19 #Long Covid #Mitochondria #Phase II trial #University of Oxford

Encouraging trial results for long Covid fatigue treatment

Researchers from the University of Oxford have reported findings from a Phase II clinical trial investigating the efficacy of an investigational treatment against long Covid fatigue. The study found that participants given the treatment, AXA1125, developed by US pharmaceutical company Axcella Therapeutics, felt less fatigued than… Read More

#Editor's Choice #News

Hospital patient on ventilator
#Covid-19 #Covid-19 treatment #FDA #InflaRx #Monoclonal antibodies

FDA okays Gohibic for emergency use in Covid-19 patients

Gohibic (vilobelimab) has been granted an Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) for the treatment of Covid-19 in hospitalised adults. The monoclonal anti-human complement factor C5a antibody should be initiated within 48 hours of receiving invasive mechanical ventilation (IMV) or… Read More

#News #Trending News

Covid-19
#Biotechnology #Covid-19 #Immunology / Virology & Vaccines

Developing next generation pan-SARS-CoV-2 vaccines 

SpyBiotech, a UK-based biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has received a grant of $4,094,561 from the Bill & Melinda Gates Foundation to further develop its novel SpyVector platform.   This project will harness SpyBio’s ‘plug… Read More

#Covid-19 #News

T cell attacking Covid-19
#Covid-19 #Covid-19 vaccine #Immune response #Immunology / Virology & Vaccines #SARS-CoV-2 #T cell activation

Covid-19 causes long-term damage to the immune system

New findings suggest that the SARS-CoV-2 virus damages an important immune-cell response. The quality of CD8+ T cell response to two doses of the Pfizer-BioNTech Covid-19 vaccine was considerably lower in people with prior SARS-CoV-2 infection compared to people without prior infection, the US study found. Read More

#News #Trending News

Monocyte
#Covid-19 #Immune cells #Immune response #Immunology / Virology & Vaccines #Long Covid

Malfunctioning monocytes could be drug target in long Covid

Researchers have shown for the first time that malfunctioning behaviour of a type of immune cell is linked to specific symptoms of long Covid. Normally functioning monocytes, made in the bone marrow, would travel through the blood to the lungs where they surround and kill the… Read More

#Editor's Choice #News

#Biopharmaceuticals #Cell and gene therapy #Covid-19 #Drug development

Overcoming inefficiencies to improve access to cell and gene therapy 

The cell and gene therapy (CGT) landscape has grown significantly in the past year. Between the 24 therapies already approved by the FDA1 and a marked increase in clinical trials, widespread accessibility to precision medicine feels within reach. Lauren Collison, PhD, Senior VP, Operations & Site Head, KBI Biopharma, reflects.  … Read More

#Exclusive Content #Opinion

#Autoimmune disease #Biopharmaceuticals #Covid-19 #Long Covid #Multiple sclerosis #Neurodegenerative disorders

€25 million to support clinical developments against long Covid

GeNeuro, a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe consequences of Covid-19, (PASC, post-Covid or long Covid), has entered into a credit agreement for a total amount of up to €25 million with the… Read More

#News

#Covid-19 #Drug development #Drug discovery #HIV #Immunity #Immunology / Virology & Vaccines #Vaccines

New episode of the DDW Highlights podcast

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Our news highlights this week focus on research into vaccines, with… Read More

#News

#Covid-19 #Drug development #Drug discovery #HIV #Immunity #Immunology / Virology & Vaccines #Vaccines

This week in drug discovery (20-24 February)

News round-up for 20-24 February by DDW Digital Content Editor Diana Spencer.  Our news highlights this week focus on research into vaccines, with good news for the treatment or prevention of various challenging conditions, including Covid-19, Strep A and HIV. Particularly interesting is the announcement that a new class… Read More

#News

Vaccine
#Covid booster #Covid-19 #Immunology / Virology & Vaccines #Phase III trial #Vaxxinity

New Covid-19 booster outperforms approved vaccines

Covid-19 booster candidate UB-612 has achieved its immunogenicity endpoints in a head-to-head trial against three vaccine platforms: mRNA (Pfizer-BioNTech’s BNT162b2), adenovirus vector (AstraZeneca’s ChAdOx1-S), and inactivated virus (Sinopharm’s BIBP).  The results show UB-612 elicits superior neutralising antibody titers and seroconversion rates against… Read More

#News #Trending News

Covid-19 vaccination
#Cardiovascular disease #Covid-19 #Covid-19 vaccine #Immunology / Virology & Vaccines

Covid-19 vaccination reduces risk of cardiac events

Researchers have revealed that vaccination against Covid-19 is associated with fewer heart attacks, strokes, and other cardiovascular issues among people who were infected with SARS-CoV-2.  The conclusions are based on analysis of the most extensive datasets in the United States by a team from the Icahn School… Read More

#News #Trending News

Clinical trials
#Breast cancer #Cancer research #Clinical research #Clinical trials #Covid-19 #Oncology

What are the top disease areas for clinical drug trials?

Breast cancer retained its position as the most-studied disease area in clinical trials in 2022, according to a recent report by analytics company Phesi. Here, we take a look at the top four disease areas and some of the key developments in 2022.  1. Breast cancer In April, Biotech ISA… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Covid-19 #Immunology / Virology & Vaccines

AI use in repurposing drugs for Covid-19

Listen to this article on the DDW podcast: In 2020, AI models predicted the efficacy of repurposed drugs for Covid-19. Clinical trials revealed eight out of nine predictions were correct. Here Imran S Haque, VP Data Science at Recursion describes the journey of the AI platform behind those predictions. The Covid-19… Read More

#Exclusive Content